Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2013

View Archived Issues

Investigators report discovery of novel allosteric MEK inhibitor CInQ-03

Phase I/II results presented for the long-acting rhGH in children

Moffitt Cancer Center forms strategic partnership with Advinus Therapeutics

Horizon Discovery and Hisun enter agreement

Researchers present a novel mouse model of human myelofibrosis

Belrose Pharma acquires Enzon's advanced drug formulation technology

Vivus study shows avanafil is effective for sexual activity within 15 minutes

QGC-001 is well tolerated at doses of up to 1250 mg

Results announced from first pivotal trial of ALK's allergy immunotherapy tablet

Application seeking approval of tofogliflozin submitted in Japan

MC1R SNPs found to be associated with the severity of RLS

BerGenBio begins phase I trial of BGB-324

Pharmaxis enrolls first subject into pediatric trial evaluating Bronchitol in cystic fibrosis

BioSante Pharmaceuticals and ANI Pharmaceuticals complete merger

PsiOxus Therapeutics begins second study of ColoAd1 vaccine

Intezyne Technologies acquires Niiki Pharma

Novel apoptosis inducers presented by researchers in Barcelona

Novartis prepares novel HDAC4 inhibitors

Paladin's NDA for Impavido granted priority review

ChemoCentryx synthesizes new chemokine receptor antagonists

Boehringer Ingelheim presents novel agents for diabetes and obesity

Volibris tablets granted new Japanese orphan drug designation

OncoSec completes enrollment in phase II ImmunoPulse trial in metastatic melanoma

Merck Serono initiates phase I study of ALX-0761

Evoltra launched in Japan

A new university spin-out raises funding to develop new anticoagulant drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.